Foundayo (Orforglipron) in the UAE: The Once-Daily GLP-1 Tablet
Dr. Hecham Harb
Consultant Endocrinologist & Medical Director
Book Your Consultation
- Specialist consultation
- Personalized Coaching
- Body Composition Analysis
Foundayo (orforglipron) is a once-daily GLP-1 tablet for chronic weight management in adults. The Emirates Drug Establishment approved it in the UAE, where it has been available to eligible patients since May 2026. In a large clinical trial called ATTAIN-1, patients lost around 12% of their total body weight on average, with some achieving around 15%. At Endocare, your doctor will prescribe Foundayo only after a medical assessment that includes blood tests from the last three months.
- Foundayo is a tablet instead of an injection, taken once daily with or without food, at any time of day.
- Foundayo is approved for chronic weight management in both the UAE and the US. The Emirates Drug Establishment approved it in the UAE, while the US Food and Drug Administration (FDA) approved it on 1 April 2026.
- Foundayo is used in adults with obesity, and in adults with overweight who also have a metabolic condition such as type 2 diabetes or high blood pressure.
- The Foundayo prescribing information sets a starting dose of 0.8 mg, at least 30 days at each dose and a maximum of 17.2 mg once a day.
- Endocare requires blood test results from within the last three months before prescribing any weight loss medication.
- The prescribing information advises a non-oral or barrier contraceptive method for 30 days after starting Foundayo and after each dose increase.
01 What is Foundayo, and how does it work?
Foundayo (orforglipron) is a once-daily tablet that targets the same GLP-1 receptor as injectable GLP-1 weight loss medications. It helps regulate appetite and food intake, but unlike weekly GLP-1 injections, it is taken by mouth.
The Foundayo prescribing information describes orforglipron as a GLP-1 receptor agonist. It mimics a natural gut hormone that signals fullness to the brain and slows stomach emptying, helping to reduce appetite and food intake.
The Emirates Drug Establishment describes Foundayo as an oral treatment to be taken once daily without food or water intake restrictions. Your endocrinologist will plan treatment over months and review your dose at each monthly follow-up appointment.
Our endocrinologists prescribe Foundayo alongside nutrition, physical activity, sleep and coaching support, because this combination can help maintain your results.
02 Who is Foundayo for?
The US prescribing information approves Foundayo for adults only. The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sets the threshold for weight management medication at a body mass index of 30 or above. It falls to 27 or above where the patient also has a metabolic health problem such as high blood pressure or type 2 diabetes.
The same guidance reports that weight management medications work best when combined with a lifestyle programme. Our endocrinologists work with the same thresholds.
The number on the scale is only the starting point. Your endocrinologist will review your medical history, current medications, blood tests and body composition results before deciding whether Foundayo is the right treatment for you or whether another weight loss option may be more appropriate. The World Health Organization describes obesity as a chronic disease, which is why treatment requires ongoing management and regular review rather than a one-off prescription.
Thyroid disease and insulin resistance can both make weight management more difficult. Identifying either does not delay treatment; it helps your endocrinologist tailor the treatment plan to address the underlying issue as well as your weight.
Patients should not decide by themselves to start a GLP-1 medication. A doctor’s review is critical to ensure the treatment is safe and appropriate for the individual.
03 How much weight can you lose on Foundayo?
In ATTAIN-1, a large Phase 3 clinical trial in adults with obesity or overweight, participants taking the highest dose of orforglipron lost around 12% of their body weight on average, with some achieving 15% or more. Weight loss of this magnitude is often associated with clinically meaningful improvements in blood pressure, lipids and blood sugar, and some patients with prediabetes may return to the normal glucose range.
The trial ran for 72 weeks, so its average describes the result after more than a year of treatment. Some patients start to see weight changes from around week two, while others take longer to respond. Early weight loss also does not necessarily continue at the same rate.
Clinical trial averages describe groups of patients, and individual results vary. How much weight you lose can depend on your starting point, how you respond to treatment and the lifestyle support around it. Our guide to your first month on Foundayo describes what to expect at the starting dose.
04 What is the Foundayo dose range?
Foundayo is available in six doses: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg once daily, with 17.2 mg being the maximum. Treatment starts at 0.8 mg, and the prescribing information recommends at least 30 days at each dose before any increase.
The dose is reviewed with your endocrinologist at each monthly follow-up. The 0.8 mg and 2.5 mg doses are steps in the dose escalation, and your maintenance dose is not necessarily the highest one.
Foundayo is taken once daily with or without food, and Eli Lilly’s patient information states that it can be taken at any time of day. The Wegovy pill is taken differently: in the morning on an empty stomach, with up to half a cup of water. It is followed by a 30-minute wait before food, other drinks and other medications. The morning timing comes from the US prescribing information, and the UK product information sets no time of day.
Our Foundayo dosage guide explains how your endocrinologist decides each dose step, how to take the tablet and what to do if you miss a dose.
05 What are the side effects of Foundayo?
Most side effects of Foundayo are digestive. In the two 72-week trials reported in the prescribing information, nausea affected 26% to 35% of patients taking Foundayo, depending on the dose, compared with 10% of those taking a placebo.
The other common side effects in those trials were constipation, diarrhoea, vomiting, indigestion and abdominal pain, followed by headache, abdominal swelling, tiredness, belching, acid reflux, flatulence and hair loss.
Side effects such as nausea or constipation can be particularly pronounced in the first few days at a new dose. They often improve as your body adjusts, although some symptoms last longer. Not every patient experiences them. If you experience nausea or constipation, your endocrinologist can adjust the pace of dose increases and, where needed, prescribe medication to help manage these side effects.
Severe abdominal pain that does not settle, with or without vomiting, can be a sign of pancreatitis. Stop taking Foundayo and seek medical advice immediately if this happens. The same applies if you notice a lump or swelling in your neck, hoarseness or difficulty swallowing.
Our page on Foundayo side effects explains each side effect and the rarer risks, and our article on whether medical weight loss is safe describes how doctors monitor treatment.
06 Who should not take Foundayo?
Foundayo is not suitable for everyone, and your endocrinologist will check this before prescribing. The prescribing information states that it should not be used by anyone with a personal or family history of medullary thyroid carcinoma, by anyone with multiple endocrine neoplasia syndrome type 2, or by anyone with a known serious hypersensitivity to orforglipron.
The prescribing information does not recommend Foundayo in severe liver impairment, or together with another GLP-1 medication. A history of pancreatitis, gallbladder disease, diabetic retinopathy or significant gastrointestinal disease does not automatically rule out treatment. Your endocrinologist will assess each of these as part of your medical history.
Foundayo should not be used during pregnancy because it may harm an unborn baby. Breastfeeding is also not recommended while taking Foundayo. Oral contraceptive pills may be less effective during treatment, and a non-oral or barrier method is advised for 30 days after starting Foundayo and for 30 days after each dose increase. Please tell your endocrinologist if you are planning a pregnancy.
Please also tell your doctor that you take Foundayo before any planned surgery or procedure, because the prescribing information lists a risk of food being inhaled into the lungs during general anaesthesia or deep sedation.
07 How does Foundayo compare with the injectable treatments?
The leading injectable treatments still produce greater average weight loss, while Foundayo offers the convenience of a daily tablet without injections. These figures come from separate clinical trials with different participants and durations. They give a general comparison and do not rank the medications directly.
| Option | How it works | Route | Average weight loss in trials (% of body weight) |
|---|---|---|---|
| Foundayo (orforglipron) | GLP-1 receptor agonist | Once-daily tablet | Around 12%, with some patients achieving 15% or more (ATTAIN-1 trial, 72 weeks) |
| Mounjaro (tirzepatide) | Dual GIP and GLP-1 receptor agonist | Once-weekly injection | Around 20% over 72 weeks (SURMOUNT-1 trial) |
| Wegovy injection (semaglutide 2.4 mg) | GLP-1 receptor agonist | Once-weekly injection | Around 15% over 68 weeks (STEP 1 trial) |
| The Wegovy pill (oral semaglutide 25 mg) | GLP-1 receptor agonist | Once-daily tablet | Around 17% over 64 weeks (OASIS 4 trial) |
Each figure is the average result from a Phase 3 clinical trial in adults with obesity or overweight, named in the final column. Of the four, Mounjaro, which contains tirzepatide, produced the highest average weight loss in its trial. Two of the four, Foundayo and the Wegovy pill, are tablets. Our article on GLP-1 pills explains which tablets are available in the UAE and how they work.
Ozempic and the Wegovy injection both contain semaglutide. Ozempic is approved for type 2 diabetes, and Wegovy is the semaglutide medication approved for weight management. At Endocare, Ozempic is considered for weight management only in patients with type 2 diabetes or prediabetes. Ozempic is not approved for weight management or for prediabetes, so using it for weight management outside the treatment of type 2 diabetes, including in prediabetes, is off-label. Our comparison of Ozempic and Wegovy explains how the two medications differ.
Foundayo may be appropriate for patients who prefer a tablet, or who have found weekly injections difficult to maintain. Your endocrinologist will discuss these differences with you before treatment is agreed. Our comparisons of Foundayo and Mounjaro and of Foundayo and the Wegovy pill set out the differences in detail, and our article comparing Mounjaro, Ozempic and Wegovy covers the three injections.
08 Is Foundayo available in the UAE?
Yes, on prescription. The Emirates Drug Establishment announced its approval of Foundayo on 3 April 2026, when the UAE became the second country to register it, and Foundayo has been available to eligible patients since May 2026.
Foundayo is dispensed through licensed pharmacies. Endocare prescribes it at our Dubai and Abu Dhabi clinics, and our pages on Foundayo in Dubai and Foundayo in Abu Dhabi cover each city. Medication delivery is free across the UAE and typically arrives the same day.
We recommend obtaining your medication only through a licensed pharmacy. The World Health Organization warns that online purchases and informal markets make falsified medical products more difficult to monitor. Medication bought outside the licensed supply chain carries no assurance of its contents and no medical supervision, which our article on buying weight loss medication online explains.
09 How much does Foundayo cost in the UAE?
Foundayo treatment at Endocare is offered as part of our medical weight loss programme, starting at AED 1,790 for the first month and AED 1,990 per month thereafter. The programme includes your medication, unlimited specialist consultations and one-to-one coaching during the month, body composition analysis at every visit, scheduled blood tests and free medication delivery across the UAE. Endocare adds no markup to the official pharmacy price of your medication.
In UAE pharmacies, a pack of 30 Foundayo tablets costs between AED 773 and AED 1,599, depending on the dose. Our Foundayo price page lists the price of each dose.
Insurance coverage for weight loss treatment in the UAE varies by policy and is often limited, so we recommend checking your individual coverage before starting treatment. Our care coordinators can also help you in this process.
10 How Endocare prescribes Foundayo
Endocare’s endocrinologists see patients at our Dubai clinic in Dubai Healthcare City. Your first appointment is a full medical assessment, not simply a prescription visit. Your endocrinologist will review your medical history and any relevant blood tests, assess your weight and metabolic health, and discuss whether Foundayo or another weight loss treatment is the right option for you. Where possible, your first appointment takes place in person at Endocare’s Dubai clinic, as the physical examination and body composition analysis cannot be completed remotely.
Your endocrinologist will review blood tests from the last three months before prescribing. If your results are out of date, the clinic can arrange the required tests. If they are current, your assessment and prescription can usually be completed at your first appointment. At Endocare, body composition analysis is included free of charge at every consultation. Body composition analysis estimates body fat, muscle mass and body water. Repeated measurements help your endocrinologist understand how your body is changing beyond the number on the scale.
Monthly follow-up appointments can be held in person at the clinic or online. We recommend the first consultation in person, as it includes a physical examination and body composition analysis. Endocare’s lifestyle coaches will build your nutrition and activity plan around your body composition results and your daily routine.
If Foundayo is not the right treatment for you, your endocrinologist will explain why and set out the alternatives, including the injectable options and the Wegovy pill. Being assessed for one treatment does not commit you to it.
Our Abu Dhabi clinic in Al Bateen offers the same weight loss services as our Dubai clinic.
11 FAQ
What kind of drug is Foundayo?
Foundayo is a GLP-1 receptor agonist taken as a tablet. A review in the journal Drugs describes orforglipron as an orally administered, non-peptide GLP-1 receptor agonist. It is used for chronic weight management, alongside a reduced-calorie diet and increased physical activity.
Is Foundayo effective for weight loss?
For many patients, yes. In ATTAIN-1, a 72-week Phase 3 clinical trial in adults with obesity or overweight, the average weight loss at the highest dose was around 12%. Results vary between patients, and your endocrinologist will review your progress at each monthly follow-up.
Which is better, Foundayo or Wegovy?
Neither option is necessarily better. The right choice depends on your individual assessment, how well you tolerate treatment and what you can realistically sustain long term. Your endocrinologist will work through these factors with you. The Wegovy injection and the Wegovy pill produced higher average weight loss in their own trials, while Foundayo has no food or water restrictions.
Do you take Foundayo on an empty stomach?
No. Foundayo can be taken with or without food, at any time of day. The Wegovy pill, by contrast, is taken on an empty stomach, and the US prescribing information asks for it to be taken in the morning.
How long does it take to see results on Foundayo?
It varies between patients. Some notice a change in appetite within the first few weeks, while others take longer, and both patterns are normal. Your endocrinologist will review your progress at each monthly follow-up appointment.
Can you switch from a weight loss injection to Foundayo?
For many patients, yes. Some patients move to a tablet because injections are difficult to maintain, and others move to a tablet for maintenance after reaching their target weight. Your endocrinologist will plan the change with you, because the prescribing information does not recommend taking Foundayo together with another GLP-1 medication. Our article on switching from an injection to a tablet explains the options.
What happens when you stop taking Foundayo?
Appetite may return, and some weight regain is possible. When it is time to come off Foundayo, your endocrinologist may lower the dose in steps, which is Endocare’s clinical practice, and coaching continues throughout. A gradual reduction in dose is an individual clinical approach, not a proven standard of care, and it has not been shown to prevent weight regain. If your weight starts rising after treatment stops, contact your endocrinologist early. They can review your lifestyle plan and whether further treatment is appropriate. Our article on what happens when you stop taking Foundayo explains this in more detail.
If you are considering Foundayo, the next step is a weight loss consultation. At our Dubai clinic, your endocrinologist will assess whether Foundayo is appropriate for you, explain what your blood tests and body composition analysis show, and set out your treatment options.
Our Dubai clinic is located in Building 27, Block B, Unit 504 B, Dubai Healthcare City. Opening hours are Sunday 10:00-20:00, Monday 08:30-18:30, and Tuesday to Thursday 10:00-20:00. The clinic is closed on Fridays. You can call the Dubai clinic on +971 4 285 3885.
Our Abu Dhabi clinic is at Al Bateen, Tower C2, Unit 104, and you can call it on +971 2 582 6178. You can also send us a message on WhatsApp.
Book Your Consultation
- Specialist consultation
- Personalized Coaching
- Body Composition Analysis